Success Story: 16 Days to EB-1B Success for a Senior Scientist under Premium Processing
Client’s Testimonial:
“Thank you so much for all your support with my application. It was a pleasure for me as well to work with your very competent team.”
On December 5th, 2025, we received another EB-1B (Outstanding Professors and Researchers) approval for a Senior Scientist in the Field of Nanomedicine (Approval Notice).
General Field: Nanomedicine
Position at the Time of Case Filing: Senior Scientist
Approval Notice Date: December 5th, 2025
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
When a Senior Scientist in the field of nanomedicine approached our firm with an exceptional record in experimental medicine, our team recognized the exceptional caliber of the client’s achievements. With over 32,000 successful cases informing our strategy, we undertook the challenge of presenting this scientist’s accomplishments to USCIS with precision and impact.
The Research Profile
Holding a Ph.D. in Experimental Medicine, the client has dedicated their career to developing targeted nanoparticle-based drug delivery platforms addressing cancer, cardiovascular disease, and neurodegeneration. Their pioneering work with human serum albumin nanoparticles has established new pathways for precision medicine, reducing treatment side effects while improving therapeutic efficacy.
Our Strategic Approach
Our team crafted a comprehensive petition highlighting the client’s exceptional standing within the international research community. We documented 1,399 citations to the client’s work. We highlighted their authorship of 14 peer-reviewed journal articles (4 first-authored), 1 peer-reviewed conference paper, and 7 first-authored abstracts.
Critical to our presentation was evidence of international recognition: citations spanning five continents and a record of service as a peer reviewer for at least 13 manuscripts. We secured four expert recommendation letters. One expert stated that:
“By providing a precise, targeted, and safer drug delivery platform, [Client]’s work has applications that improve patient survival, enhance quality of life, and advance global efforts to reduce cancer mortality and morbidity.”
The Outcome
The petition achieved EB-1B approval in precisely 16 days under premium processing without a Request for Evidence, a testament both to the client’s outstanding qualifications and our comprehensive documentation strategy. This exceptional timeline reflects the strength of evidence presented and the clarity with which we established the client’s international recognition.
We extend our congratulations to this remarkable researcher and anticipate their continued contributions to advancing therapeutic innovation within the United States.